Eversept Partners LP Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Eversept Partners LP boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 117.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 2,992,895 shares of the biotechnology company’s stock after acquiring an additional 1,619,270 shares during the period. BioCryst Pharmaceuticals comprises approximately 1.2% of Eversept Partners LP’s investment portfolio, making the stock its 18th largest position. Eversept Partners LP’s holdings in BioCryst Pharmaceuticals were worth $23,345,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after buying an additional 482,494 shares during the period. RA Capital Management L.P. purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $123,452,000. Deerfield Management Company L.P. raised its holdings in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after buying an additional 7,477,000 shares during the period. State Street Corp raised its holdings in BioCryst Pharmaceuticals by 12.9% in the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock valued at $86,371,000 after buying an additional 1,265,773 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in BioCryst Pharmaceuticals by 22.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,225,986 shares of the biotechnology company’s stock valued at $39,665,000 after buying an additional 947,431 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BCRX has been the subject of several research reports. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Evercore initiated coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 target price for the company. Needham & Company LLC dropped their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, Wedbush dropped their target price on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.70.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $8.95 on Thursday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $10.32. The company has a market cap of $2.27 billion, a PE ratio of -5.03 and a beta of 0.57. The business has a 50-day simple moving average of $8.92 and a 200-day simple moving average of $8.16.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.